RA
ATNM icon

Royce & Associates’s Actinium Pharmaceuticals ATNM Stock Holding History

Royce & Associates’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-50,000
Closed -$94K – 838
2024
Q3 		$94K Hold
50,000
– – ﹤0.01% 846
2024
Q2 		$370K Hold
50,000
– – ﹤0.01% 810
2024
Q1 		$392K Hold
50,000
– – ﹤0.01% 805
2023
Q4 		$254K Hold
50,000
– – ﹤0.01% 831
2023
Q3 		$296K Hold
50,000
– – ﹤0.01% 850
2023
Q2 		$371K Hold
50,000
– – ﹤0.01% 859
2023
Q1 		$473K Buy
+50,000
New +$528K ﹤0.01% 843

Other funds holding ATNM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $27.2B AUM 43.16% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Royce & Associates's ATNM Position: Q4 2024 in Review

Royce & Associates sold out of Actinium Pharmaceuticals (ATNM) in Q4 2024, closing a stake of 50,000 shares — an estimated $94K sold.

Royce & Associates first reported a position in ATNM in Q1 2023 and held it in 7 quarters. The position peaked at $473K in Q1 2023. 69 funds tracked by Wall St. Rank hold ATNM as of Q4 2024.

  • Royce & Associates reported no remaining Actinium Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Royce & Associates sold 50,000 Actinium Pharmaceuticals shares in Q4 2024, an estimated $94K.
  • Royce & Associates first reported a position in Actinium Pharmaceuticals in Q1 2023 and held it in 7 quarters.
  • Royce & Associates's Actinium Pharmaceuticals position peaked at $473K in Q1 2023.
  • 69 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2024.

Based on Royce & Associates's 13F filing for Q4 2024, filed 10 Feb 2025.